

Ontario Public Drug Programs

Notice from the Executive Officer: Funding of Inflectra (infliximab) under the Ontario Drug Benefit Program

November 30, 2016

Effective **November 30 2016**, Inflectra (infliximab) will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients in the treatment of inflammatory bowel disease.

Inflectra will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for the following indications:

- Crohn's Disease
- Ulcerative Colitis
- Severe Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis

Details of the LU criteria will be also be posted in the November 2016 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282